221 related articles for article (PubMed ID: 26335795)
1. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N
Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795
[TBL] [Abstract][Full Text] [Related]
2. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus.
Tocoian A; Buchan P; Kirby H; Soranson J; Zamacona M; Walley R; Mitchell N; Esfandiari E; Wagner F; Oliver R
Lupus; 2015 Sep; 24(10):1045-56. PubMed ID: 25784719
[TBL] [Abstract][Full Text] [Related]
3. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge.
Ferrant JL; Benjamin CD; Cutler AH; Kalled SL; Hsu YM; Garber EA; Hess DM; Shapiro RI; Kenyon NS; Harlan DM; Kirk AD; Burkly LC; Taylor FR
Int Immunol; 2004 Nov; 16(11):1583-94. PubMed ID: 15466914
[TBL] [Abstract][Full Text] [Related]
4. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases.
Xie JH; Yamniuk AP; Borowski V; Kuhn R; Susulic V; Rex-Rabe S; Yang X; Zhou X; Zhang Y; Gillooly K; Brosius R; Ravishankar R; Waggie K; Mink K; Price L; Rehfuss R; Tamura J; An Y; Cheng L; Abramczyk B; Ignatovich O; Drew P; Grant S; Bryson JW; Suchard S; Salter-Cid L; Nadler S; Suri A
J Immunol; 2014 May; 192(9):4083-92. PubMed ID: 24670803
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.
Early GS; Zhao W; Burns CM
J Immunol; 1996 Oct; 157(7):3159-64. PubMed ID: 8816428
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody.
Muralidharan S; Njenga M; Garron T; Bondensgaard K; Paolini JF
J Pharmacol Exp Ther; 2022 Apr; 381(1):12-21. PubMed ID: 35078863
[TBL] [Abstract][Full Text] [Related]
8. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.
Karpusas M; Lucci J; Ferrant J; Benjamin C; Taylor FR; Strauch K; Garber E; Hsu YM
Structure; 2001 Apr; 9(4):321-9. PubMed ID: 11525169
[TBL] [Abstract][Full Text] [Related]
9. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions.
Chirmule N; Raper SE; Burkly L; Thomas D; Tazelaar J; Hughes JV; Wilson JM
J Virol; 2000 Apr; 74(7):3345-52. PubMed ID: 10708452
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism.
Nakamura M; Tanaka Y; Satoh T; Kawai M; Hirakata M; Kaburaki J; Kawakami Y; Ikeda Y; Kuwana M
Rheumatology (Oxford); 2006 Feb; 45(2):150-6. PubMed ID: 16188945
[TBL] [Abstract][Full Text] [Related]
13. The role of CD40 ligand in systemic lupus erythematosus.
Yazdany J; Davis J
Lupus; 2004; 13(5):377-80. PubMed ID: 15230296
[TBL] [Abstract][Full Text] [Related]
14. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice.
Robles-Carrillo L; Meyer T; Hatfield M; Desai H; Dávila M; Langer F; Amaya M; Garber E; Francis JL; Hsu YM; Amirkhosravi A
J Immunol; 2010 Aug; 185(3):1577-83. PubMed ID: 20585032
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients.
Marken J; Muralidharan S; Giltiay NV
Arthritis Res Ther; 2021 Jan; 23(1):5. PubMed ID: 33407802
[TBL] [Abstract][Full Text] [Related]
17. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients.
Sidiropoulos PI; Boumpas DT
Lupus; 2004; 13(5):391-7. PubMed ID: 15230298
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody.
Arpinati M; Chirumbolo G; Rondelli D
Eur J Haematol; 2008 Apr; 80(4):322-30. PubMed ID: 18081708
[TBL] [Abstract][Full Text] [Related]
19. Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis.
Ramanujam M; Steffgen J; Visvanathan S; Mohan C; Fine JS; Putterman C
Autoimmun Rev; 2020 Nov; 19(11):102668. PubMed ID: 32942031
[TBL] [Abstract][Full Text] [Related]
20. Platelet pro-aggregatory effects of CD40L monoclonal antibody.
Mirabet M; Barrabés JA; Quiroga A; Garcia-Dorado D
Mol Immunol; 2008 Feb; 45(4):937-44. PubMed ID: 17959249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
